We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003.
The study, called Inspire Duchenne, began earlier this year at two sites in the US, and has already expanded to a third site. Solid has now confirmed it will expand enrollment to 43 participants, across a total of six sites in North America by the end of the year. The trial is also on track to expand to Europe in the new year.
Click here to read Solid’s letter to the community.